{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T08:16:06Z","timestamp":1790496966405,"version":"4.1.0"},"reference-count":149,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:00:00Z","timestamp":1654473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:00:00Z","timestamp":1654473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006668","name":"Oregon Health and Science University","doi-asserted-by":"publisher","award":["Macklin Fund"],"award-info":[{"award-number":["Macklin Fund"]}],"id":[{"id":"10.13039\/100006668","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mitochondrial diseases are a group of rare, heterogeneous diseases caused by gene mutations in both nuclear and mitochondrial genomes that result in defects in mitochondrial function. They are responsible for significant morbidity and mortality as they affect multiple organ systems and particularly those with high energy-utilizing tissues, such as the nervous system, skeletal muscle, and cardiac muscle. Virtually no effective treatments exist for these patients, despite the urgent need. As the majority of these conditions are monogenic and caused by mutations in nuclear genes, gene replacement is a highly attractive therapeutic strategy. Adeno-associated virus (AAV) is a well-characterized gene replacement vector, and its safety profile and ability to transduce quiescent cells nominates it as a potential gene therapy vehicle for several mitochondrial diseases. Indeed, AAV vector-based gene replacement is currently being explored in clinical trials for one mitochondrial disease (Leber hereditary optic neuropathy) and preclinical studies have been published investigating this strategy in other mitochondrial diseases. This review summarizes the preclinical findings of AAV vector-based gene replacement therapy for mitochondrial diseases including Leigh syndrome, Barth syndrome, ethylmalonic encephalopathy, and others.\n<\/jats:p>","DOI":"10.1186\/s13023-022-02324-7","type":"journal-article","created":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T05:02:38Z","timestamp":1654491758000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["AAV-vector based gene therapy for mitochondrial disease: progress and future perspectives"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8745-9724","authenticated-orcid":false,"given":"Allison R.","family":"Hanaford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon-Jae","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,6]]},"reference":[{"issue":"14","key":"2324_CR1","doi-asserted-by":"publisher","first-page":"R551","DOI":"10.1016\/j.cub.2006.06.054","volume":"16","author":"HM McBride","year":"2006","unstructured":"McBride HM, Neuspiel M, Wasiak S. Mitochondria: more than just a powerhouse. Curr Biol. 2006;16(14):R551\u201360.","journal-title":"Curr Biol"},{"issue":"1","key":"2324_CR2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/jimd.12104","volume":"43","author":"K Thompson","year":"2020","unstructured":"Thompson K, Collier JJ, Glasgow RIC, Robertson FM, Pyle A, Blakely EL, et al. Recent advances in understanding the molecular genetic basis of mitochondrial disease. J Inherit Metab Dis. 2020;43(1):36\u201350.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"2324_CR3","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.ajhg.2010.03.002","volume":"86","author":"D Ghezzi","year":"2010","unstructured":"Ghezzi D, Sevrioukova I, Invernizzi F, Lamperti C, Mora M, D\u2019Adamo P, et al. Severe X-linked mitochondrial encephalomyopathy associated with a mutation in apoptosis-inducing factor. Am J Hum Genet. 2010;86(4):639\u201349.","journal-title":"Am J Hum Genet"},{"issue":"8","key":"2324_CR4","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1136\/jmedgenet-2014-102961","volume":"52","author":"L Zong","year":"2015","unstructured":"Zong L, Guan J, Ealy M, Zhang Q, Wang D, Wang H, et al. Mutations in apoptosis-inducing factor cause X-linked recessive auditory neuropathy spectrum disorder. J Med Genet. 2015;52(8):523\u201331.","journal-title":"J Med Genet"},{"issue":"2","key":"2324_CR5","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/ana.24551","volume":"79","author":"NJ Lake","year":"2016","unstructured":"Lake NJ, Compton AG, Rahman S, Thorburn DR. Leigh syndrome: One disorder, more than 75 monogenic causes. Ann Neurol. 2016;79(2):190\u2013203.","journal-title":"Ann Neurol"},{"issue":"5","key":"2324_CR6","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/ana.24362","volume":"77","author":"GS Gorman","year":"2015","unstructured":"Gorman GS, Schaefer AM, Ng Y, Gomez N, Blakely EL, Alston CL, et al. Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease. Ann Neurol. 2015;77(5):753\u20139.","journal-title":"Ann Neurol"},{"issue":"Pt 8","key":"2324_CR7","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1093\/brain\/awg170","volume":"126","author":"D Skladal","year":"2003","unstructured":"Skladal D, Halliday J, Thorburn DR. Minimum birth prevalence of mitochondrial respiratory chain disorders in children. Brain. 2003;126(Pt 8):1905\u201312.","journal-title":"Brain"},{"issue":"3","key":"2324_CR8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10815-018-1370-7","volume":"36","author":"M Pompei","year":"2019","unstructured":"Pompei M, Pompei F. Overcoming bioethical, legal, and hereditary barriers to mitochondrial replacement therapy in the USA. J Assist Reprod Genet. 2019;36(3):383\u201393.","journal-title":"J Assist Reprod Genet"},{"issue":"3","key":"2324_CR9","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1042\/EBC20170114","volume":"62","author":"M Hirano","year":"2018","unstructured":"Hirano M, Emmanuele V, Quinzii CM. Emerging therapies for mitochondrial diseases. Essays Biochem. 2018;62(3):467\u201381.","journal-title":"Essays Biochem"},{"issue":"4","key":"2324_CR10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","volume":"21","author":"C Li","year":"2020","unstructured":"Li C, Samulski RJ. Engineering adeno-associated virus vectors for gene therapy. Nat Rev Genet. 2020;21(4):255\u201372.","journal-title":"Nat Rev Genet"},{"issue":"1\u20132","key":"2324_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1089\/hum.2019.220","volume":"31","author":"P Tornabene","year":"2020","unstructured":"Tornabene P, Trapani I. Can adeno-associated viral vectors deliver effectively large genes? Hum Gene Ther. 2020;31(1\u20132):47\u201356.","journal-title":"Hum Gene Ther"},{"issue":"15","key":"2324_CR12","doi-asserted-by":"publisher","first-page":"6969","DOI":"10.1128\/JVI.75.15.6969-6976.2001","volume":"75","author":"H Nakai","year":"2001","unstructured":"Nakai H, Yant SR, Storm TA, Fuess S, Meuse L, Kay MA. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol. 2001;75(15):6969\u201376.","journal-title":"J Virol"},{"issue":"1","key":"2324_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41587-020-0741-7","volume":"39","author":"GN Nguyen","year":"2021","unstructured":"Nguyen GN, Everett JK, Kafle S, Roche AM, Raymond HE, Leiby J, et al. A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells. Nat Biotechnol. 2021;39(1):47\u201355.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"2324_CR14","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1089\/hum.2017.048","volume":"28","author":"KI Berns","year":"2017","unstructured":"Berns KI, Muzyczka N. AAV: an overview of unanswered questions. Hum Gene Ther. 2017;28(4):308\u201313.","journal-title":"Hum Gene Ther"},{"issue":"3","key":"2324_CR15","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1128\/JVI.01686-08","volume":"83","author":"BC Schnepp","year":"2009","unstructured":"Schnepp BC, Jensen RL, Clark KR, Johnson PR. Infectious molecular clones of adeno-associated virus isolated directly from human tissues. J Virol. 2009;83(3):1456\u201364.","journal-title":"J Virol"},{"issue":"5","key":"2324_CR16","doi-asserted-by":"publisher","first-page":"750","DOI":"10.3390\/pharmaceutics13050750","volume":"13","author":"MA Korneyenkov","year":"2021","unstructured":"Korneyenkov MA, Zamyatnin AA Jr. Next step in gene delivery: modern approaches and further perspectives of AAV tropism modification. Pharmaceutics. 2021;13(5):750.","journal-title":"Pharmaceutics"},{"issue":"9","key":"2324_CR17","doi-asserted-by":"publisher","first-page":"e76310","DOI":"10.1371\/journal.pone.0076310","volume":"8","author":"DF Aschauer","year":"2013","unstructured":"Aschauer DF, Kreuz S, Rumpel S. Analysis of transduction efficiency, tropism and axonal transport of AAV serotypes 1, 2, 5, 6, 8 and 9 in the mouse brain. PLoS ONE. 2013;8(9):e76310.","journal-title":"PLoS ONE"},{"key":"2324_CR18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/978-1-61779-370-7_6","volume":"807","author":"MS Sands","year":"2011","unstructured":"Sands MS. AAV-mediated liver-directed gene therapy. Methods Mol Biol. 2011;807:141\u201357.","journal-title":"Methods Mol Biol"},{"issue":"4","key":"2324_CR19","doi-asserted-by":"publisher","first-page":"e133392","DOI":"10.15252\/emmm.202013392","volume":"13","author":"M Pavlou","year":"2021","unstructured":"Pavlou M, Schon C, Occelli LM, Rossi A, Meumann N, Boyd RF, et al. Novel AAV capsids for intravitreal gene therapy of photoreceptor disorders. EMBO Mol Med. 2021;13(4):e133392.","journal-title":"EMBO Mol Med"},{"issue":"2","key":"2324_CR20","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nbt.3440","volume":"34","author":"BE Deverman","year":"2016","unstructured":"Deverman BE, Pravdo PL, Simpson BP, Kumar SR, Chan KY, Banerjee A, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol. 2016;34(2):204\u20139.","journal-title":"Nat Biotechnol"},{"key":"2324_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1750-1172-8-23","volume":"8","author":"SL Clarke","year":"2013","unstructured":"Clarke SL, Bowron A, Gonzalez IL, Groves SJ, Newbury-Ecob R, Clayton N, et al. Barth syndrome. Orphanet J Rare Dis. 2013;8:23.","journal-title":"Orphanet J Rare Dis"},{"key":"2324_CR22","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.gene.2019.144148","volume":"726","author":"AO Garlid","year":"2020","unstructured":"Garlid AO, Schaffer CT, Kim J, Bhatt H, Guevara-Gonzalez V, Ping P. TAZ encodes tafazzin, a transacylase essential for cardiolipin formation and central to the etiology of Barth syndrome. Gene. 2020;726:144\u20138.","journal-title":"Gene"},{"issue":"2","key":"2324_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1089\/hum.2018.020","volume":"30","author":"S Suzuki-Hatano","year":"2019","unstructured":"Suzuki-Hatano S, Saha M, Rizzo SA, Witko RL, Gosiker BJ, Ramanathan M, et al. AAV-mediated TAZ gene replacement restores mitochondrial and cardioskeletal function in Barth syndrome. Hum Gene Ther. 2019;30(2):139\u201354.","journal-title":"Hum Gene Ther"},{"key":"2324_CR24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.omtm.2019.01.007","volume":"13","author":"S Suzuki-Hatano","year":"2019","unstructured":"Suzuki-Hatano S, Saha M, Soustek MS, Kang PB, Byrne BJ, Cade WT, et al. AAV9-TAZ gene replacement ameliorates cardiac TMT proteomic profiles in a mouse model of Barth syndrome. Mol Ther Methods Clin Dev. 2019;13:167\u201379.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"8","key":"2324_CR25","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1161\/CIRCRESAHA.119.315956","volume":"126","author":"S Wang","year":"2020","unstructured":"Wang S, Li Y, Xu Y, Ma Q, Lin Z, Schlame M, et al. AAV gene therapy prevents and reverses heart failure in a murine knockout model of Barth syndrome. Circ Res. 2020;126(8):1024\u201339.","journal-title":"Circ Res"},{"issue":"1","key":"2324_CR26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/bmb\/ldx034","volume":"124","author":"A Cook","year":"2017","unstructured":"Cook A, Giunti P. Friedreich\u2019s ataxia: clinical features, pathogenesis and management. Br Med Bull. 2017;124(1):19\u201330.","journal-title":"Br Med Bull"},{"key":"2324_CR27","doi-asserted-by":"publisher","first-page":"104606","DOI":"10.1016\/j.nbd.2019.104606","volume":"132","author":"MB Delatycki","year":"2019","unstructured":"Delatycki MB, Bidichandani SI. Friedreich ataxia\u2014pathogenesis and implications for therapies. Neurobiol Dis. 2019;132:104606.","journal-title":"Neurobiol Dis"},{"issue":"3","key":"2324_CR28","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/mds.27606","volume":"34","author":"PGD Ward","year":"2019","unstructured":"Ward PGD, Harding IH, Close TG, Corben LA, Delatycki MB, Storey E, et al. Longitudinal evaluation of iron concentration and atrophy in the dentate nuclei in Friedreich ataxia. Mov Disord. 2019;34(3):335\u201343.","journal-title":"Mov Disord"},{"issue":"1\u20132","key":"2324_CR29","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jns.2011.05.023","volume":"307","author":"AY Tsou","year":"2011","unstructured":"Tsou AY, Paulsen EK, Lagedrost SJ, Perlman SL, Mathews KD, Wilmot GR, et al. Mortality in Friedreich ataxia. J Neurol Sci. 2011;307(1\u20132):46\u20139.","journal-title":"J Neurol Sci"},{"issue":"6","key":"2324_CR30","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1093\/hmg\/ddr554","volume":"21","author":"PM Vyas","year":"2012","unstructured":"Vyas PM, Tomamichel WJ, Pride PM, Babbey CM, Wang Q, Mercier J, et al. A TAT-frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich\u2019s ataxia mouse model. Hum Mol Genet. 2012;21(6):1230\u201347.","journal-title":"Hum Mol Genet"},{"issue":"9","key":"2324_CR31","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1080\/21678707.2016.1215910","volume":"4","author":"E Soragni","year":"2016","unstructured":"Soragni E, Gottesfeld JM. Translating HDAC inhibitors in Friedreich\u2019s ataxia. Expert Opin Orphan Drugs. 2016;4(9):961\u201370.","journal-title":"Expert Opin Orphan Drugs"},{"issue":"1","key":"2324_CR32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1089\/nat.2017.0703","volume":"28","author":"L Li","year":"2018","unstructured":"Li L, Shen X, Liu Z, Norrbom M, Prakash TP, O\u2019Reilly D, et al. Activation of frataxin protein expression by antisense oligonucleotides targeting the mutant expanded repeat. Nucleic Acid Ther. 2018;28(1):23\u201333.","journal-title":"Nucleic Acid Ther"},{"issue":"15","key":"2324_CR33","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1080\/14656566.2019.1639671","volume":"20","author":"A Clay","year":"2019","unstructured":"Clay A, Hearle P, Schadt K, Lynch DR. New developments in pharmacotherapy for Friedreich ataxia. Expert Opin Pharmacother. 2019;20(15):1855\u201367.","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"2324_CR34","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1093\/hmg\/9.8.1219","volume":"9","author":"M Cossee","year":"2000","unstructured":"Cossee M, Puccio H, Gansmuller A, Koutnikova H, Dierich A, LeMeur M, et al. Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. Hum Mol Genet. 2000;9(8):1219\u201326.","journal-title":"Hum Mol Genet"},{"issue":"2","key":"2324_CR35","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/84818","volume":"27","author":"H Puccio","year":"2001","unstructured":"Puccio H, Simon D, Cossee M, Criqui-Filipe P, Tiziano F, Melki J, et al. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet. 2001;27(2):181\u20136.","journal-title":"Nat Genet"},{"issue":"5","key":"2324_CR36","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nm.3510","volume":"20","author":"M Perdomini","year":"2014","unstructured":"Perdomini M, Belbellaa B, Monassier L, Reutenauer L, Messaddeq N, Cartier N, et al. Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich\u2019s ataxia. Nat Med. 2014;20(5):542\u20137.","journal-title":"Nat Med"},{"key":"2324_CR37","doi-asserted-by":"crossref","unstructured":"Voyager's CNS gene therapy. Nat Biotechnol. 2019;37(3):204.","DOI":"10.1038\/s41587-019-0062-x"},{"key":"2324_CR38","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.omtm.2020.08.018","volume":"19","author":"B Belbellaa","year":"2020","unstructured":"Belbellaa B, Reutenauer L, Messaddeq N, Monassier L, Puccio H. High levels of frataxin overexpression lead to mitochondrial and cardiac toxicity in mouse models. Mol Ther Methods Clin Dev. 2020;19:120\u201338.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"8","key":"2324_CR39","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/j.ymthe.2018.05.006","volume":"26","author":"F Piguet","year":"2018","unstructured":"Piguet F, de Montigny C, Vaucamps N, Reutenauer L, Eisenmann A, Puccio H. Rapid and complete reversal of sensory ataxia by gene therapy in a novel model of Friedreich ataxia. Mol Ther. 2018;26(8):1940\u201352.","journal-title":"Mol Ther"},{"issue":"16","key":"2324_CR40","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1056\/NEJM199610173351601","volume":"335","author":"A Durr","year":"1996","unstructured":"Durr A, Cossee M, Agid Y, Campuzano V, Mignard C, Penet C, et al. Clinical and genetic abnormalities in patients with Friedreich\u2019s ataxia. N Engl J Med. 1996;335(16):1169\u201375.","journal-title":"N Engl J Med"},{"key":"2324_CR41","doi-asserted-by":"publisher","first-page":"14044","DOI":"10.1038\/mtm.2014.44","volume":"1","author":"C Gerard","year":"2014","unstructured":"Gerard C, Xiao X, Filali M, Coulombe Z, Arsenault M, Couet J, et al. An AAV9 coding for frataxin clearly improved the symptoms and prolonged the life of Friedreich ataxia mouse models. Mol Ther Methods Clin Dev. 2014;1:14044.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2324_CR42","doi-asserted-by":"publisher","first-page":"e30054","DOI":"10.7554\/eLife.30054","volume":"6","author":"V Chandran","year":"2017","unstructured":"Chandran V, Gao K, Swarup V, Versano R, Dong H, Jordan MC, et al. Inducible and reversible phenotypes in a novel mouse model of Friedreich\u2019s Ataxia. Elife. 2017;6:e30054.","journal-title":"Elife"},{"issue":"6","key":"2324_CR43","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1097\/NEN.0000000000000195","volume":"74","author":"NJ Lake","year":"2015","unstructured":"Lake NJ, Bird MJ, Isohanni P, Paetau A. Leigh syndrome: neuropathology and pathogenesis. J Neuropathol Exp Neurol. 2015;74(6):482\u201392.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3","key":"2324_CR44","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ymgme.2015.12.004","volume":"117","author":"M Gerards","year":"2016","unstructured":"Gerards M, Sallevelt SC, Smeets HJ. Leigh syndrome: Resolving the clinical and genetic heterogeneity paves the way for treatment options. Mol Genet Metab. 2016;117(3):300\u201312.","journal-title":"Mol Genet Metab"},{"issue":"6","key":"2324_CR45","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1111\/cge.13139","volume":"93","author":"L Chen","year":"2018","unstructured":"Chen L, Cui Y, Jiang D, Ma CY, Tse HF, Hwu WL, et al. Management of Leigh syndrome: current status and new insights. Clin Genet. 2018;93(6):1131\u201340.","journal-title":"Clin Genet"},{"issue":"2","key":"2324_CR46","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10545-016-0011-5","volume":"40","author":"K Sofou","year":"2017","unstructured":"Sofou K, Dahlin M, Hallbook T, Lindefeldt M, Viggedal G, Darin N. Ketogenic diet in pyruvate dehydrogenase complex deficiency: short- and long-term outcomes. J Inherit Metab Dis. 2017;40(2):237\u201345.","journal-title":"J Inherit Metab Dis"},{"issue":"6165","key":"2324_CR47","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1126\/science.1244360","volume":"342","author":"SC Johnson","year":"2013","unstructured":"Johnson SC, Yanos ME, Kayser EB, Quintana A, Sangesland M, Castanza A, et al. mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome. Science. 2013;342(6165):1524\u20138.","journal-title":"Science"},{"issue":"9","key":"2324_CR48","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1002\/acn3.50846","volume":"6","author":"A Sage-Schwaede","year":"2019","unstructured":"Sage-Schwaede A, Engelstad K, Salazar R, Curcio A, Khandji A, Garvin JH Jr, et al. Exploring mTOR inhibition as treatment for mitochondrial disease. Ann Clin Transl Neurol. 2019;6(9):1877\u201381.","journal-title":"Ann Clin Transl Neurol"},{"issue":"10","key":"2324_CR49","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/gt.2017.53","volume":"24","author":"I Di Meo","year":"2017","unstructured":"Di Meo I, Marchet S, Lamperti C, Zeviani M, Viscomi C. AAV9-based gene therapy partially ameliorates the clinical phenotype of a mouse model of Leigh syndrome. Gene Ther. 2017;24(10):661\u20137.","journal-title":"Gene Ther"},{"issue":"6","key":"2324_CR50","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1093\/brain\/awaa105","volume":"143","author":"R Reynaud-Dulaurier","year":"2020","unstructured":"Reynaud-Dulaurier R, Benegiamo G, Marrocco E, Al-Tannir R, Surace EM, Auwerx J, et al. Gene replacement therapy provides benefit in an adult mouse model of Leigh syndrome. Brain. 2020;143(6):1686\u201396.","journal-title":"Brain"},{"key":"2324_CR51","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.omtm.2020.04.026","volume":"17","author":"P Silva-Pinheiro","year":"2020","unstructured":"Silva-Pinheiro P, Cerutti R, Luna-Sanchez M, Zeviani M, Viscomi C. A single intravenous injection of AAV-PHP.B-hNDUFS4 ameliorates the phenotype of Ndufs4 (-\/-) mice. Mol Ther Methods Clin Dev. 2020;17:1071\u20138.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"2324_CR52","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/jmg.2003.014316","volume":"41","author":"P Benit","year":"2004","unstructured":"Benit P, Slama A, Cartault F, Giurgea I, Chretien D, Lebon S, et al. Mutant NDUFS3 subunit of mitochondrial complex I causes Leigh syndrome. J Med Genet. 2004;41(1):14\u20137.","journal-title":"J Med Genet"},{"issue":"12","key":"2324_CR53","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/s10038-018-0505-0","volume":"63","author":"X Lou","year":"2018","unstructured":"Lou X, Shi H, Wen S, Li Y, Wei X, Xie J, et al. A Novel NDUFS3 mutation in a Chinese patient with severe Leigh syndrome. J Hum Genet. 2018;63(12):1269\u201372.","journal-title":"J Hum Genet"},{"issue":"2","key":"2324_CR54","doi-asserted-by":"publisher","first-page":"e10674","DOI":"10.15252\/emmm.201910674","volume":"12","author":"CV Pereira","year":"2020","unstructured":"Pereira CV, Peralta S, Arguello T, Bacman SR, Diaz F, Moraes CT. Myopathy reversion in mice after restauration of mitochondrial complex I. EMBO Mol Med. 2020;12(2):e10674.","journal-title":"EMBO Mol Med"},{"issue":"7","key":"2324_CR55","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/j.cell.2012.11.053","volume":"151","author":"DU Mick","year":"2012","unstructured":"Mick DU, Dennerlein S, Wiese H, Reinhold R, Pacheu-Grau D, Lorenzi I, et al. MITRAC links mitochondrial protein translocation to respiratory-chain assembly and translational regulation. Cell. 2012;151(7):1528\u201341.","journal-title":"Cell"},{"issue":"6","key":"2324_CR56","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.bbabio.2011.09.007","volume":"1817","author":"A Hannappel","year":"2012","unstructured":"Hannappel A, Bundschuh FA, Ludwig B. Role of Surf1 in heme recruitment for bacterial COX biogenesis. Biochim Biophys Acta. 2012;1817(6):928\u201337.","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"2324_CR57","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/hmg\/ddl477","volume":"16","author":"C Dell'agnello","year":"2007","unstructured":"Dell\u2019agnello C, Leo S, Agostino A, Szabadkai G, Tiveron C, Zulian A, et al. Increased longevity and refractoriness to Ca(2+)-dependent neurodegeneration in Surf1 knockout mice. Hum Mol Genet. 2007;16(4):431\u201344.","journal-title":"Hum Mol Genet"},{"key":"2324_CR58","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.omtm.2021.09.001","volume":"23","author":"Q Ling","year":"2021","unstructured":"Ling Q, Rioux M, Hu Y, Lee M, Gray SJ. Adeno-associated viral vector serotype 9-based gene replacement therapy for SURF1-related Leigh syndrome. Mol Ther Methods Clin Dev. 2021;23:158\u201368.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"16","key":"2324_CR59","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/sj.gt.3301514","volume":"8","author":"DM McCarty","year":"2001","unstructured":"McCarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 2001;8(16):1248\u201354.","journal-title":"Gene Ther"},{"issue":"7","key":"2324_CR60","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/mt.2009.71","volume":"17","author":"S Duque","year":"2009","unstructured":"Duque S, Joussemet B, Riviere C, Marais T, Dubreil L, Douar AM, et al. Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther. 2009;17(7):1187\u201396.","journal-title":"Mol Ther"},{"issue":"2","key":"2324_CR61","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1086\/381653","volume":"74","author":"V Tiranti","year":"2004","unstructured":"Tiranti V, D\u2019Adamo P, Briem E, Ferrari G, Mineri R, Lamantea E, et al. Ethylmalonic encephalopathy is caused by mutations in ETHE1, a gene encoding a mitochondrial matrix protein. Am J Hum Genet. 2004;74(2):239\u201352.","journal-title":"Am J Hum Genet"},{"issue":"2","key":"2324_CR62","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/nm.1907","volume":"15","author":"V Tiranti","year":"2009","unstructured":"Tiranti V, Viscomi C, Hildebrandt T, Di Meo I, Mineri R, Tiveron C, et al. Loss of ETHE1, a mitochondrial dioxygenase, causes fatal sulfide toxicity in ethylmalonic encephalopathy. Nat Med. 2009;15(2):200\u20135.","journal-title":"Nat Med"},{"issue":"3","key":"2324_CR63","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s10545-011-9408-3","volume":"35","author":"C Giordano","year":"2012","unstructured":"Giordano C, Viscomi C, Orlandi M, Papoff P, Spalice A, Burlina A, et al. Morphologic evidence of diffuse vascular damage in human and in the experimental model of ethylmalonic encephalopathy. J Inherit Metab Dis. 2012;35(3):451\u20138.","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"2324_CR64","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00415-004-0426-z","volume":"251","author":"S Grosso","year":"2004","unstructured":"Grosso S, Balestri P, Mostardini R, Federico A, De Stefano N. Brain mitochondrial impairment in ethylmalonic encephalopathy. J Neurol. 2004;251(6):755\u20136.","journal-title":"J Neurol"},{"issue":"2","key":"2324_CR65","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0887-8994(97)00048-9","volume":"17","author":"MT Garcia-Silva","year":"1997","unstructured":"Garcia-Silva MT, Ribes A, Campos Y, Garavaglia B, Arenas J. Syndrome of encephalopathy, petechiae, and ethylmalonic aciduria. Pediatr Neurol. 1997;17(2):165\u201370.","journal-title":"Pediatr Neurol"},{"issue":"2","key":"2324_CR66","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1089\/ars.2010.3520","volume":"15","author":"I Di Meo","year":"2011","unstructured":"Di Meo I, Fagiolari G, Prelle A, Viscomi C, Zeviani M, Tiranti V. Chronic exposure to sulfide causes accelerated degradation of cytochrome c oxidase in ethylmalonic encephalopathy. Antioxid Redox Signal. 2011;15(2):353\u201362.","journal-title":"Antioxid Redox Signal"},{"issue":"8","key":"2324_CR67","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/nm.2188","volume":"16","author":"C Viscomi","year":"2010","unstructured":"Viscomi C, Burlina AB, Dweikat I, Savoiardo M, Lamperti C, Hildebrandt T, et al. Combined treatment with oral metronidazole and N-acetylcysteine is effective in ethylmalonic encephalopathy. Nat Med. 2010;16(8):869\u201371.","journal-title":"Nat Med"},{"issue":"2","key":"2324_CR68","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s11011-016-9928-5","volume":"32","author":"M Kilic","year":"2017","unstructured":"Kilic M, Dedeoglu O, Gocmen R, Kesici S, Yuksel D. Successful treatment of a patient with ethylmalonic encephalopathy by intravenous N-acetylcysteine. Metab Brain Dis. 2017;32(2):293\u20136.","journal-title":"Metab Brain Dis"},{"issue":"1","key":"2324_CR69","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ymgme.2018.02.008","volume":"124","author":"M Boyer","year":"2018","unstructured":"Boyer M, Sowa M, Di Meo I, Eftekharian S, Steenari MR, Tiranti V, et al. Response to medical and a novel dietary treatment in newborn screen identified patients with ethylmalonic encephalopathy. Mol Genet Metab. 2018;124(1):57\u201363.","journal-title":"Mol Genet Metab"},{"issue":"6","key":"2324_CR70","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/ajmg.a.61104","volume":"179","author":"A Tam","year":"2019","unstructured":"Tam A, AlDhaheri NS, Mysore K, Tessier ME, Goss J, Fernandez LA, et al. Improved clinical outcome following liver transplant in patients with ethylmalonic encephalopathy. Am J Med Genet A. 2019;179(6):1015\u20139.","journal-title":"Am J Med Genet A"},{"issue":"9","key":"2324_CR71","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/emmm.201201433","volume":"4","author":"I Di Meo","year":"2012","unstructured":"Di Meo I, Auricchio A, Lamperti C, Burlina A, Viscomi C, Zeviani M. Effective AAV-mediated gene therapy in a mouse model of ethylmalonic encephalopathy. EMBO Mol Med. 2012;4(9):1008\u201314.","journal-title":"EMBO Mol Med"},{"issue":"2","key":"2324_CR72","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s13311-013-0177-6","volume":"10","author":"AW El-Hattab","year":"2013","unstructured":"El-Hattab AW, Scaglia F. Mitochondrial DNA depletion syndromes: review and updates of genetic basis, manifestations, and therapeutic options. Neurotherapeutics. 2013;10(2):186\u201398.","journal-title":"Neurotherapeutics"},{"key":"2324_CR73","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3389\/fgene.2018.00669","volume":"9","author":"D Pacitti","year":"2018","unstructured":"Pacitti D, Levene M, Garone C, Nirmalananthan N, Bax BE. Mitochondrial neurogastrointestinal encephalomyopathy: into the fourth decade, what we have learned so far. Front Genet. 2018;9:669.","journal-title":"Front Genet"},{"issue":"3","key":"2324_CR74","doi-asserted-by":"publisher","first-page":"e1002035","DOI":"10.1371\/journal.pgen.1002035","volume":"7","author":"E Gonzalez-Vioque","year":"2011","unstructured":"Gonzalez-Vioque E, Torres-Torronteras J, Andreu AL, Marti R. Limited dCTP availability accounts for mitochondrial DNA depletion in mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). PLoS Genet. 2011;7(3):e1002035.","journal-title":"PLoS Genet"},{"issue":"3","key":"2324_CR75","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1001\/archneur.64.3.435","volume":"64","author":"H Yavuz","year":"2007","unstructured":"Yavuz H, Ozel A, Christensen M, Christensen E, Schwartz M, Elmaci M, et al. Treatment of mitochondrial neurogastrointestinal encephalomyopathy with dialysis. Arch Neurol. 2007;64(3):435\u20138.","journal-title":"Arch Neurol"},{"issue":"3","key":"2324_CR76","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/ana.24724","volume":"80","author":"R De Giorgio","year":"2016","unstructured":"De Giorgio R, Pironi L, Rinaldi R, Boschetti E, Caporali L, Capristo M, et al. Liver transplantation for mitochondrial neurogastrointestinal encephalomyopathy. Ann Neurol. 2016;80(3):448\u201355.","journal-title":"Ann Neurol"},{"issue":"Pt 4","key":"2324_CR77","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1093\/brain\/aww013","volume":"139","author":"C Dionisi-Vici","year":"2016","unstructured":"Dionisi-Vici C, Diodato D, Torre G, Picca S, Pariante R, Giuseppe Picardo S, et al. Liver transplant in ethylmalonic encephalopathy: a new treatment for an otherwise fatal disease. Brain. 2016;139(Pt 4):1045\u201351.","journal-title":"Brain"},{"issue":"Pt 10","key":"2324_CR78","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/brain\/awv226","volume":"138","author":"JP Halter","year":"2015","unstructured":"Halter JP, Michael W, Schupbach M, Mandel H, Casali C, Orchard K, et al. Allogeneic haematopoietic stem cell transplantation for mitochondrial neurogastrointestinal encephalomyopathy. Brain. 2015;138(Pt 10):2847\u201358.","journal-title":"Brain"},{"issue":"14","key":"2324_CR79","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1212\/WNL.0b013e3182a6cb4b","volume":"81","author":"BE Bax","year":"2013","unstructured":"Bax BE, Bain MD, Scarpelli M, Filosto M, Tonin P, Moran N. Clinical and biochemical improvements in a patient with MNGIE following enzyme replacement. Neurology. 2013;81(14):1269\u201371.","journal-title":"Neurology"},{"issue":"1","key":"2324_CR80","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ymgme.2020.03.001","volume":"130","author":"K Kripps","year":"2020","unstructured":"Kripps K, Nakayuenyongsuk W, Shayota BJ, Berquist W, Gomez-Ospina N, Esquivel CO, et al. Successful liver transplantation in mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). Mol Genet Metab. 2020;130(1):58\u201364.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"2324_CR81","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1093\/hmg\/ddn401","volume":"18","author":"LC Lopez","year":"2009","unstructured":"Lopez LC, Akman HO, Garcia-Cazorla A, Dorado B, Marti R, Nishino I, et al. Unbalanced deoxynucleotide pools cause mitochondrial DNA instability in thymidine phosphorylase-deficient mice. Hum Mol Genet. 2009;18(4):714\u201322.","journal-title":"Hum Mol Genet"},{"issue":"8","key":"2324_CR82","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/gt.2011.24","volume":"18","author":"J Torres-Torronteras","year":"2011","unstructured":"Torres-Torronteras J, Gomez A, Eixarch H, Palenzuela L, Pizzorno G, Hirano M, et al. Hematopoietic gene therapy restores thymidine phosphorylase activity in a cell culture and a murine model of MNGIE. Gene Ther. 2011;18(8):795\u2013806.","journal-title":"Gene Ther"},{"issue":"9","key":"2324_CR83","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1089\/hum.2015.160","volume":"27","author":"J Torres-Torronteras","year":"2016","unstructured":"Torres-Torronteras J, Cabrera-Perez R, Barba I, Costa C, de Luna N, Andreu AL, et al. Long-term restoration of thymidine phosphorylase function and nucleoside homeostasis using hematopoietic gene therapy in a Murine model of mitochondrial neurogastrointestinal encephalomyopathy. Hum Gene Ther. 2016;27(9):656\u201367.","journal-title":"Hum Gene Ther"},{"key":"2324_CR84","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.omtm.2018.01.001","volume":"8","author":"R Yadak","year":"2018","unstructured":"Yadak R, Cabrera-Perez R, Torres-Torronteras J, Bugiani M, Haeck JC, Huston MW, et al. Preclinical efficacy and safety evaluation of hematopoietic stem cell gene therapy in a mouse model of MNGIE. Mol Ther Methods Clin Dev. 2018;8:152\u201365.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"6","key":"2324_CR85","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1089\/hum.2017.133","volume":"29","author":"J Torres-Torronteras","year":"2018","unstructured":"Torres-Torronteras J, Cabrera-Perez R, Vila-Julia F, Viscomi C, Camara Y, Hirano M, et al. Long-term sustained effect of liver-targeted adeno-associated virus gene therapy for mitochondrial neurogastrointestinal encephalomyopathy. Hum Gene Ther. 2018;29(6):708\u201318.","journal-title":"Hum Gene Ther"},{"issue":"8","key":"2324_CR86","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1089\/hum.2018.217","volume":"30","author":"R Cabrera-Perez","year":"2019","unstructured":"Cabrera-Perez R, Vila-Julia F, Hirano M, Mingozzi F, Torres-Torronteras J, Marti R. Alpha-1-antitrypsin promoter improves the efficacy of an adeno-associated virus vector for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Hum Gene Ther. 2019;30(8):985\u201398.","journal-title":"Hum Gene Ther"},{"issue":"Pt 5","key":"2324_CR87","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1093\/brain\/awu068","volume":"137","author":"B Garcia-Diaz","year":"2014","unstructured":"Garcia-Diaz B, Garone C, Barca E, Mojahed H, Gutierrez P, Pizzorno G, et al. Deoxynucleoside stress exacerbates the phenotype of a mouse model of mitochondrial neurogastrointestinal encephalopathy. Brain. 2014;137(Pt 5):1337\u201349.","journal-title":"Brain"},{"key":"2324_CR88","doi-asserted-by":"publisher","first-page":"103133","DOI":"10.1016\/j.ebiom.2020.103133","volume":"62","author":"F Vila-Julia","year":"2020","unstructured":"Vila-Julia F, Cabrera-Perez R, Camara Y, Molina-Berenguer M, Lope-Piedrafita S, Hirano M, et al. Efficacy of adeno-associated virus gene therapy in a MNGIE murine model enhanced by chronic exposure to nucleosides. EBioMedicine. 2020;62:103133.","journal-title":"EBioMedicine"},{"issue":"1","key":"2324_CR89","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1373\/clinchem.2003.026179","volume":"50","author":"R Marti","year":"2004","unstructured":"Marti R, Spinazzola A, Tadesse S, Nishino I, Nishigaki Y, Hirano M. Definitive diagnosis of mitochondrial neurogastrointestinal encephalomyopathy by biochemical assays. Clin Chem. 2004;50(1):120\u20134.","journal-title":"Clin Chem"},{"issue":"1","key":"2324_CR90","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/mt.2013.230","volume":"22","author":"E Bottani","year":"2014","unstructured":"Bottani E, Giordano C, Civiletto G, Di Meo I, Auricchio A, Ciusani E, et al. AAV-mediated liver-specific MPV17 expression restores mtDNA levels and prevents diet-induced liver failure. Mol Ther. 2014;22(1):10\u20137.","journal-title":"Mol Ther"},{"issue":"5","key":"2324_CR91","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/ng1765","volume":"38","author":"A Spinazzola","year":"2006","unstructured":"Spinazzola A, Viscomi C, Fernandez-Vizarra E, Carrara F, D\u2019Adamo P, Calvo S, et al. MPV17 encodes an inner mitochondrial membrane protein and is mutated in infantile hepatic mitochondrial DNA depletion. Nat Genet. 2006;38(5):570\u20135.","journal-title":"Nat Genet"},{"issue":"1","key":"2324_CR92","doi-asserted-by":"publisher","first-page":"e1005779","DOI":"10.1371\/journal.pgen.1005779","volume":"12","author":"I Dalla Rosa","year":"2016","unstructured":"Dalla Rosa I, Camara Y, Durigon R, Moss CF, Vidoni S, Akman G, et al. MPV17 loss causes deoxynucleotide insufficiency and slow DNA replication in mitochondria. PLoS Genet. 2016;12(1):e1005779.","journal-title":"PLoS Genet"},{"issue":"1","key":"2324_CR93","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jhep.2008.08.019","volume":"50","author":"R Parini","year":"2009","unstructured":"Parini R, Furlan F, Notarangelo L, Spinazzola A, Uziel G, Strisciuglio P, et al. Glucose metabolism and diet-based prevention of liver dysfunction in MPV17 mutant patients. J Hepatol. 2009;50(1):215\u201321.","journal-title":"J Hepatol"},{"issue":"4","key":"2324_CR94","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1002\/humu.23387","volume":"39","author":"AW El-Hattab","year":"2018","unstructured":"El-Hattab AW, Wang J, Dai H, Almannai M, Staufner C, Alfadhel M, et al. MPV17-related mitochondrial DNA maintenance defect: new cases and review of clinical, biochemical, and molecular aspects. Hum Mutat. 2018;39(4):461\u201370.","journal-title":"Hum Mutat"},{"issue":"1","key":"2324_CR95","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/hmg\/ddn309","volume":"18","author":"C Viscomi","year":"2009","unstructured":"Viscomi C, Spinazzola A, Maggioni M, Fernandez-Vizarra E, Massa V, Pagano C, et al. Early-onset liver mtDNA depletion and late-onset proteinuric nephropathy in Mpv17 knockout mice. Hum Mol Genet. 2009;18(1):12\u201326.","journal-title":"Hum Mol Genet"},{"issue":"8","key":"2324_CR96","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1136\/jmedgenet-2017-105012","volume":"55","author":"C Garone","year":"2018","unstructured":"Garone C, Taylor RW, Nascimento A, Poulton J, Fratter C, Dominguez-Gonzalez C, et al. Retrospective natural history of thymidine kinase 2 deficiency. J Med Genet. 2018;55(8):515\u201321.","journal-title":"J Med Genet"},{"issue":"2","key":"2324_CR97","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S0014-5793(98)01711-6","volume":"443","author":"L Wang","year":"1999","unstructured":"Wang L, Munch-Petersen B, Herrstrom Sjoberg A, Hellman U, Bergman T, Jornvall H, et al. Human thymidine kinase 2: molecular cloning and characterisation of the enzyme activity with antiviral and cytostatic nucleoside substrates. FEBS Lett. 1999;443(2):170\u20134.","journal-title":"FEBS Lett"},{"issue":"2","key":"2324_CR98","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/ana.25506","volume":"86","author":"C Dominguez-Gonzalez","year":"2019","unstructured":"Dominguez-Gonzalez C, Madruga-Garrido M, Mavillard F, Garone C, Aguirre-Rodriguez FJ, Donati MA, et al. Deoxynucleoside therapy for thymidine kinase 2-deficient myopathy. Ann Neurol. 2019;86(2):293\u2013303.","journal-title":"Ann Neurol"},{"issue":"16","key":"2324_CR99","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1093\/hmg\/ddn143","volume":"17","author":"HO Akman","year":"2008","unstructured":"Akman HO, Dorado B, Lopez LC, Garcia-Cazorla A, Vila MR, Tanabe LM, et al. Thymidine kinase 2 (H126N) knockin mice show the essential role of balanced deoxynucleotide pools for mitochondrial DNA maintenance. Hum Mol Genet. 2008;17(16):2433\u201340.","journal-title":"Hum Mol Genet"},{"issue":"5","key":"2324_CR100","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/ana.24922","volume":"81","author":"C Lopez-Gomez","year":"2017","unstructured":"Lopez-Gomez C, Levy RJ, Sanchez-Quintero MJ, Juanola-Falgarona M, Barca E, Garcia-Diaz B, et al. Deoxycytidine and deoxythymidine treatment for thymidine kinase 2 deficiency. Ann Neurol. 2017;81(5):641\u201352.","journal-title":"Ann Neurol"},{"issue":"4","key":"2324_CR101","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/ana.26185","volume":"90","author":"C Lopez-Gomez","year":"2021","unstructured":"Lopez-Gomez C, Sanchez-Quintero MJ, Lee EJ, Kleiner G, Tadesse S, Xie J, et al. Synergistic deoxynucleoside and gene therapies for thymidine kinase 2 deficiency. Ann Neurol. 2021;90(4):640\u201352.","journal-title":"Ann Neurol"},{"issue":"9","key":"2324_CR102","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.15252\/emmm.201506159","volume":"8","author":"A Janer","year":"2016","unstructured":"Janer A, Prudent J, Paupe V, Fahiminiya S, Majewski J, Sgarioto N, et al. SLC25A46 is required for mitochondrial lipid homeostasis and cristae maintenance and is responsible for Leigh syndrome. EMBO Mol Med. 2016;8(9):1019\u201338.","journal-title":"EMBO Mol Med"},{"issue":"4\u20135","key":"2324_CR103","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1159\/000464445","volume":"17","author":"MB Hammer","year":"2017","unstructured":"Hammer MB, Ding J, Mochel F, Eleuch-Fayache G, Charles P, Coutelier M, et al. SLC25A46 mutations associated with autosomal recessive cerebellar ataxia in North African families. Neurodegener Dis. 2017;17(4\u20135):208\u201312.","journal-title":"Neurodegener Dis"},{"issue":"8","key":"2324_CR104","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1002\/mds.26716","volume":"31","author":"G Charlesworth","year":"2016","unstructured":"Charlesworth G, Balint B, Mencacci NE, Carr L, Wood NW, Bhatia KP. SLC25A46 mutations underlie progressive myoclonic ataxia with optic atrophy and neuropathy. Mov Disord. 2016;31(8):1249\u201351.","journal-title":"Mov Disord"},{"issue":"8","key":"2324_CR105","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/ng.3354","volume":"47","author":"AJ Abrams","year":"2015","unstructured":"Abrams AJ, Hufnagel RB, Rebelo A, Zanna C, Patel N, Gonzalez MA, et al. Mutations in SLC25A46, encoding a UGO1-like protein, cause an optic atrophy spectrum disorder. Nat Genet. 2015;47(8):926\u201332.","journal-title":"Nat Genet"},{"issue":"11","key":"2324_CR106","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1093\/brain\/aww212","volume":"139","author":"J Wan","year":"2016","unstructured":"Wan J, Steffen J, Yourshaw M, Mamsa H, Andersen E, Rudnik-Schoneborn S, et al. Loss of function of SLC25A46 causes lethal congenital pontocerebellar hypoplasia. Brain. 2016;139(11):2877\u201390.","journal-title":"Brain"},{"issue":"4","key":"2324_CR107","doi-asserted-by":"publisher","first-page":"e1006656","DOI":"10.1371\/journal.pgen.1006656","volume":"13","author":"ME Terzenidou","year":"2017","unstructured":"Terzenidou ME, Segklia A, Kano T, Papastefanaki F, Karakostas A, Charalambous M, et al. Novel insights into SLC25A46-related pathologies in a genetic mouse model. PLoS Genet. 2017;13(4):e1006656.","journal-title":"PLoS Genet"},{"issue":"4","key":"2324_CR108","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/hmg\/ddz277","volume":"29","author":"L Yang","year":"2020","unstructured":"Yang L, Slone J, Li Z, Lou X, Hu YC, Queme LF, et al. Systemic administration of AAV-Slc25a46 mitigates mitochondrial neuropathy in Slc25a46-\/- mice. Hum Mol Genet. 2020;29(4):649\u201361.","journal-title":"Hum Mol Genet"},{"issue":"5","key":"2324_CR109","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1136\/bjo.2009.174912","volume":"95","author":"MM Liu","year":"2011","unstructured":"Liu MM, Tuo J, Chan CC. Gene therapy for ocular diseases. Br J Ophthalmol. 2011;95(5):604\u201312.","journal-title":"Br J Ophthalmol"},{"issue":"10097","key":"2324_CR110","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","volume":"390","author":"S Russell","year":"2017","unstructured":"Russell S, Bennett J, Wellman JA, Chung DC, Yu ZF, Tillman A, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390(10097):849\u201360.","journal-title":"Lancet"},{"issue":"12","key":"2324_CR111","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1007\/s12325-019-01113-2","volume":"36","author":"C Karaarslan","year":"2019","unstructured":"Karaarslan C. Leber\u2019s hereditary optic neuropathy as a promising disease for gene therapy development. Adv Ther. 2019;36(12):3299\u2013307.","journal-title":"Adv Ther"},{"issue":"6","key":"2324_CR112","doi-asserted-by":"publisher","first-page":"165743","DOI":"10.1016\/j.bbadis.2020.165743","volume":"1866","author":"T Bahr","year":"2020","unstructured":"Bahr T, Welburn K, Donnelly J, Bai Y. Emerging model systems and treatment approaches for Leber\u2019s hereditary optic neuropathy: challenges and opportunities. Biochim Biophys Acta Mol Basis Dis. 2020;1866(6):165743.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"7","key":"2324_CR113","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s40265-016-0574-3","volume":"76","author":"KA Lyseng-Williamson","year":"2016","unstructured":"Lyseng-Williamson KA. Idebenone: a review in Leber\u2019s hereditary optic neuropathy. Drugs. 2016;76(7):805\u201313.","journal-title":"Drugs"},{"key":"2324_CR114","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3389\/fcell.2016.00085","volume":"4","author":"LW Cole","year":"2016","unstructured":"Cole LW. The evolution of per-cell organelle number. Front Cell Dev Biol. 2016;4:85.","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"2324_CR115","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nrg1606","volume":"6","author":"RW Taylor","year":"2005","unstructured":"Taylor RW, Turnbull DM. Mitochondrial DNA mutations in human disease. Nat Rev Genet. 2005;6(5):389\u2013402.","journal-title":"Nat Rev Genet"},{"issue":"573","key":"2324_CR116","doi-asserted-by":"publisher","first-page":"eaaz7423","DOI":"10.1126\/scitranslmed.aaz7423","volume":"12","author":"P Yu-Wai-Man","year":"2020","unstructured":"Yu-Wai-Man P, Newman NJ, Carelli V, Moster ML, Biousse V, Sadun AA, et al. Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy. Sci Transl Med. 2020;12(573):eaaz7423.","journal-title":"Sci Transl Med."},{"issue":"5","key":"2324_CR117","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ophtha.2020.12.012","volume":"128","author":"NJ Newman","year":"2021","unstructured":"Newman NJ, Yu-Wai-Man P, Carelli V, Moster ML, Biousse V, Vignal-Clermont C, et al. Efficacy and safety of intravitreal gene therapy for Leber hereditary optic neuropathy treated within 6 months of disease onset. Ophthalmology. 2021;128(5):649\u201360.","journal-title":"Ophthalmology"},{"key":"2324_CR118","first-page":"1668","volume":"18","author":"H Yu","year":"2012","unstructured":"Yu H, Ozdemir SS, Koilkonda RD, Chou TH, Porciatti V, Chiodo V, et al. Mutant NADH dehydrogenase subunit 4 gene delivery to mitochondria by targeting sequence-modified adeno-associated virus induces visual loss and optic atrophy in mice. Mol Vis. 2012;18:1668\u201383.","journal-title":"Mol Vis"},{"issue":"20","key":"2324_CR119","doi-asserted-by":"publisher","first-page":"E1238","DOI":"10.1073\/pnas.1119577109","volume":"109","author":"H Yu","year":"2012","unstructured":"Yu H, Koilkonda RD, Chou TH, Porciatti V, Ozdemir SS, Chiodo V, et al. Gene delivery to mitochondria by targeting modified adenoassociated virus suppresses Leber\u2019s hereditary optic neuropathy in a mouse model. Proc Natl Acad Sci U S A. 2012;109(20):E1238\u201347.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2324_CR120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1167\/iovs.06-0789","volume":"48","author":"X Qi","year":"2007","unstructured":"Qi X, Sun L, Lewin AS, Hauswirth WW, Guy J. The mutant human ND4 subunit of complex I induces optic neuropathy in the mouse. Investig Ophthalmol Vis Sci. 2007;48(1):1\u201310.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"42","key":"2324_CR121","doi-asserted-by":"publisher","first-page":"E5689","DOI":"10.1073\/pnas.1506129112","volume":"112","author":"H Yu","year":"2015","unstructured":"Yu H, Koilkonda RD, Chou TH, Porciatti V, Mehta A, Hentall ID, et al. Consequences of zygote injection and germline transfer of mutant human mitochondrial DNA in mice. Proc Natl Acad Sci U S A. 2015;112(42):E5689\u201398.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2324_CR122","doi-asserted-by":"publisher","first-page":"5587","DOI":"10.1038\/s41598-018-23836-y","volume":"8","author":"H Yu","year":"2018","unstructured":"Yu H, Porciatti V, Lewin A, Hauswirth W, Guy J. Longterm reversal of severe visual loss by mitochondrial gene transfer in a mouse model of Leber hereditary optic neuropathy. Sci Rep. 2018;8(1):5587.","journal-title":"Sci Rep"},{"issue":"2","key":"2324_CR123","doi-asserted-by":"publisher","first-page":"e230","DOI":"10.1212\/NXG.0000000000000230","volume":"4","author":"J Grier","year":"2018","unstructured":"Grier J, Hirano M, Karaa A, Shepard E, Thompson JLP. Diagnostic odyssey of patients with mitochondrial disease: results of a survey. Neurol Genet. 2018;4(2):e230.","journal-title":"Neurol Genet"},{"key":"2324_CR124","doi-asserted-by":"publisher","first-page":"e066288","DOI":"10.1136\/bmj-2021-066288","volume":"375","author":"KR Schon","year":"2021","unstructured":"Schon KR, Horvath R, Wei W, Calabrese C, Tucci A, Ibanez K, et al. Use of whole genome sequencing to determine genetic basis of suspected mitochondrial disorders: cohort study. BMJ. 2021;375:e066288.","journal-title":"BMJ"},{"key":"2324_CR125","doi-asserted-by":"crossref","unstructured":"High-dose AAV gene therapy deaths. Nat Biotechnol. 2020;38(8):910.","DOI":"10.1038\/s41587-020-0642-9"},{"issue":"17\u201318","key":"2324_CR126","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1089\/hum.2020.29133.bfs","volume":"31","author":"A Philippidis","year":"2020","unstructured":"Philippidis A. After third death, Audentes\u2019 AT132 remains on clinical hold. Hum Gene Ther. 2020;31(17\u201318):908\u201310.","journal-title":"Hum Gene Ther"},{"issue":"7","key":"2324_CR127","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1089\/hum.2018.233","volume":"30","author":"Z Chai","year":"2019","unstructured":"Chai Z, Zhang X, Dobbins AL, Rigsbee KM, Wang B, Samulski RJ, Li C. Optimization of dexamethasone administration for maintaining global transduction efficacy of adeno-associated virus serotype 9. Hum Gene Ther. 2019;30(7):829\u201340. https:\/\/doi.org\/10.1089\/hum.2018.233.","journal-title":"Hum Gene Ther."},{"issue":"11","key":"2324_CR128","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1038\/mt.2011.108","volume":"19","author":"V Monteilhet","year":"2011","unstructured":"Monteilhet V, Saheb S, Boutin S, Leborgne C, Veron P, Montus MF, Moullier P, Benveniste O, Masurier C. A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. Mol Ther. 2011;19(11):2084\u201391. https:\/\/doi.org\/10.1038\/mt.2011.108","journal-title":"Mol Ther."},{"issue":"7","key":"2324_CR129","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","volume":"26","author":"C Leborgne","year":"2020","unstructured":"Leborgne C, Barbon E, Alexander JM, Hanby H, Delignat S, Cohen DM, et al. IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies. Nat Med. 2020;26(7):1096\u2013101.","journal-title":"Nat Med"},{"issue":"1","key":"2324_CR130","doi-asserted-by":"publisher","first-page":"a011437","DOI":"10.1101\/cshperspect.a011437","volume":"5","author":"V Tiranti","year":"2013","unstructured":"Tiranti V, Zeviani M. Altered sulfide (H(2)S) metabolism in ethylmalonic encephalopathy. Cold Spring Harb Perspect Biol. 2013;5(1):a011437.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2324_CR131","doi-asserted-by":"crossref","unstructured":"Gene therapies should be for all. Nat Med. 2021;27(8):1311.","DOI":"10.1038\/s41591-021-01481-9"},{"issue":"8","key":"2324_CR132","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/nn.4593","volume":"20","author":"KY Chan","year":"2017","unstructured":"Chan KY, Jang MJ, Yoo BB, Greenbaum A, Ravi N, Wu WL, et al. Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems. Nat Neurosci. 2017;20(8):1172\u20139.","journal-title":"Nat Neurosci"},{"issue":"1\u20132","key":"2324_CR133","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1089\/hum.2019.186","volume":"31","author":"AR Batista","year":"2020","unstructured":"Batista AR, King OD, Reardon CP, Davis C, Shankaracharya, Philip V, et al. Ly6a differential expression in blood\u2013brain barrier is responsible for strain specific central nervous system transduction profile of AAV-PHP.B. Hum Gene Ther. 2020;31(1\u20132):90\u2013102.","journal-title":"Hum Gene Ther"},{"issue":"5","key":"2324_CR134","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.ymthe.2019.02.013","volume":"27","author":"J Hordeaux","year":"2019","unstructured":"Hordeaux J, Yuan Y, Clark PM, Wang Q, Martino RA, Sims JJ, et al. The GPI-linked protein LY6A drives AAV-PHP.B transport across the blood\u2013brain barrier. Mol Ther. 2019;27(5):912\u201321.","journal-title":"Mol Ther"},{"issue":"11","key":"2324_CR135","doi-asserted-by":"publisher","first-page":"e0225206","DOI":"10.1371\/journal.pone.0225206","volume":"14","author":"Q Huang","year":"2019","unstructured":"Huang Q, Chan KY, Tobey IG, Chan YA, Poterba T, Boutros CL, et al. Delivering genes across the blood\u2013brain barrier: LY6A, a novel cellular receptor for AAV-PHP.B capsids. PLoS ONE. 2019;14(11):e0225206.","journal-title":"PLoS ONE"},{"issue":"3","key":"2324_CR136","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.ymthe.2018.01.018","volume":"26","author":"J Hordeaux","year":"2018","unstructured":"Hordeaux J, Wang Q, Katz N, Buza EL, Bell P, Wilson JM. The neurotropic properties of AAV-PHP.B are limited to C57BL\/6J mice. Mol Ther. 2018;26(3):664\u2013648.","journal-title":"Mol Ther"},{"key":"2324_CR137","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.neulet.2017.11.049","volume":"665","author":"Y Matsuzaki","year":"2018","unstructured":"Matsuzaki Y, Konno A, Mochizuki R, Shinohara Y, Nitta K, Okada Y, et al. Intravenous administration of the adeno-associated virus-PHP.B capsid fails to upregulate transduction efficiency in the marmoset brain. Neurosci Lett. 2018;665:182\u20138.","journal-title":"Neurosci Lett"},{"key":"2324_CR138","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.omtm.2020.12.006","volume":"20","author":"M Nonnenmacher","year":"2021","unstructured":"Nonnenmacher M, Wang W, Child MA, Ren XQ, Huang C, Ren AZ, et al. Rapid evolution of blood-brain-barrier-penetrating AAV capsids by RNA-driven biopanning. Mol Ther Methods Clin Dev. 2021;20:366\u201378.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"2324_CR139","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/jimd.12281","volume":"44","author":"RDS Pitceathly","year":"2021","unstructured":"Pitceathly RDS, Keshavan N, Rahman J, Rahman S. Moving towards clinical trials for mitochondrial diseases. J Inherit Metab Dis. 2021;44(1):22\u201341.","journal-title":"J Inherit Metab Dis"},{"issue":"43","key":"2324_CR140","doi-asserted-by":"publisher","first-page":"12292","DOI":"10.1073\/pnas.1606171113","volume":"113","author":"L Katsouri","year":"2016","unstructured":"Katsouri L, Lim YM, Blondrath K, Eleftheriadou I, Lombardero L, Birch AM, et al. PPARgamma-coactivator-1alpha gene transfer reduces neuronal loss and amyloid-beta generation by reducing beta-secretase in an Alzheimer\u2019s disease model. Proc Natl Acad Sci U S A. 2016;113(43):12292\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2324_CR141","doi-asserted-by":"publisher","first-page":"e687","DOI":"10.1212\/WNL.0000000000008861","volume":"94","author":"KL Madsen","year":"2020","unstructured":"Madsen KL, Buch AE, Cohen BH, Falk MJ, Goldsberry A, Goldstein A, et al. Safety and efficacy of omaveloxolone in patients with mitochondrial myopathy: MOTOR trial. Neurology. 2020;94(7):e687\u201398.","journal-title":"Neurology"},{"issue":"2","key":"2324_CR142","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/ana.25934","volume":"89","author":"DR Lynch","year":"2021","unstructured":"Lynch DR, Chin MP, Delatycki MB, Subramony SH, Corti M, Hoyle JC, et al. Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe Study). Ann Neurol. 2021;89(2):212\u201325.","journal-title":"Ann Neurol"},{"issue":"5\u20136","key":"2324_CR143","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1089\/hum.2020.231","volume":"32","author":"J Quinn","year":"2021","unstructured":"Quinn J, Musa A, Kantor A, McClements ME, Cehajic-Kapetanovic J, MacLaren RE, et al. Genome-editing strategies for treating human retinal degenerations. Hum Gene Ther. 2021;32(5\u20136):247\u201359.","journal-title":"Hum Gene Ther"},{"key":"2324_CR144","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3389\/fnmol.2018.00413","volume":"11","author":"N Kumar","year":"2018","unstructured":"Kumar N, Stanford W, de Solis C, Aradhana, Abraham ND, Dao TJ, et al. The development of an AAV-based CRISPR SaCas9 genome editing system that can be delivered to neurons in vivo and regulated via doxycycline and Cre-recombinase. Front Mol Neurosci. 2018;11:413.","journal-title":"Front Mol Neurosci"},{"issue":"2","key":"2324_CR145","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41591-018-0327-9","volume":"25","author":"ML Maeder","year":"2019","unstructured":"Maeder ML, Stefanidakis M, Wilson CJ, Baral R, Barrera LA, Bounoutas GS, et al. Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10. Nat Med. 2019;25(2):229\u201333.","journal-title":"Nat Med"},{"key":"2324_CR146","doi-asserted-by":"publisher","first-page":"627050","DOI":"10.3389\/fgene.2021.627050","volume":"12","author":"SA Hussain","year":"2021","unstructured":"Hussain SA, Yalvac ME, Khoo B, Eckardt S, McLaughlin KJ. Adapting CRISPR\/Cas9 system for targeting mitochondrial genome. Front Genet. 2021;12:627050.","journal-title":"Front Genet"},{"issue":"7817","key":"2324_CR147","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41586-020-2477-4","volume":"583","author":"BY Mok","year":"2020","unstructured":"Mok BY, de Moraes MH, Zeng J, Bosch DE, Kotrys AV, Raguram A, et al. A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing. Nature. 2020;583(7817):631\u20137.","journal-title":"Nature"},{"issue":"3","key":"2324_CR148","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/d41573-021-00017-7","volume":"20","author":"DA Kuzmin","year":"2021","unstructured":"Kuzmin DA, Shutova MV, Johnston NR, Smith OP, Fedorin VV, Kukushkin YS, et al. The clinical landscape for AAV gene therapies. Nat Rev Drug Discov. 2021;20(3):173\u20134.","journal-title":"Nat Rev Drug Discov"},{"key":"2324_CR149","doi-asserted-by":"publisher","unstructured":"Berman HM. The protein data bank. Nucleic Acids Res. 2000;28(1):235\u201342. https:\/\/doi.org\/10.1093\/nar\/28.1.235.","DOI":"10.1093\/nar\/28.1.235"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02324-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02324-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02324-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T06:07:36Z","timestamp":1654495656000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02324-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,6]]},"references-count":149,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2324"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02324-7","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,6]]},"assertion":[{"value":"21 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Allison R. Hanaford, Yoon-Jae Cho and Hiroyuki Nakai declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"217"}}